The Food and Drug Administration silenced one of its drug experts who raised safety concerns weeks before Merck & Co. yanked the blockbuster drug Vioxx due to increased risks for heart attack and strokes, the chairman of the Senate Finance Committee said Thursday.
He said the drugs remain a "rational choice" for patients at low risk of cardiovascular problems who have had serious gastrointestinal events (such as bleeding), but he said it would "seem prudent" to avoid them with patients who have or are at risk of cardiovascular disease.
U.S. Food and Drug Administration said the risk of an individual
